Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus METHYLPREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus METHYLPREDNISOLONE.
KENALOG IN ORABASE vs METHYLPREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Category C
Category D/X
Corticosteroid
Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."